|[February 06, 2013]
SpinalCyte, LLC Reports the Addition of Jeffrey Geesin, Ph.D. to Clinical Advisory Board
HOUSTON --(Business Wire)--
SpinalCyte, LLC, a spinal technology company focused on
autologous regrowth of the spinal disc nucleus using human dermal
fibroblasts (HDFs), today announced the addition of Jeffrey Geesin,
Ph.D. to its Clinical Advisory Board. Dr. Geesin, Former Director of
Research & Development Advanced Technologies & Regenerative Medicine at
Johnson & Johnson (JNJ), is one of the foremost authorities in the field
of regenerative medicine.
"SpinalCyte's technology has the potential to become a leader in the
fast growing field of regenerative medicine. The SpinalCyte approach
provides a simple solution to regrow the spinal disc and they can emerge
as the standard of treatment for degenerative disc disease. Their
technology can become a disruptive alternative to existing, much more
invasive procedures," remarked Dr. Geesin.
"We are excited to have an industry leader such as Dr. Geesin endorse
our technology with his involvement on or Clinical Advisory Board. Dr.
Geesin's experience and knowledge of the clinical and business climate
surrounding degenerative disc disease will provide SpinalCyte with a
valuable resource as we move into our final animal trials and we view
his involvement as a tremendous validation of our unique approach," said
Pete O'Heeron, Chief Executive Officer.
The nucleus pulposus is a gelatinous material that acts as a cushion or
shock absorber to the spinal column. It functions to distribute
hydraulic pressure in all directions within each disc under compressive
loads. The nucleus pulposus consists of chondrocytes, collagen fibrils,
and proteoglycan aggrecans.
About Jeffrey Geesin, Ph.D.
Dr. Geesin received his Ph.D. from Rutgers University. Upon graduation,
Dr. Geesin joined Johnson & Johnson ascending to Director of Research
and Development of Wound Healing Technologies. Over the next 15 years,
Dr. Geesin held numerous senior positions within Johnson & Johnson and
finished his career as the Director of Advanced Technologies and
Regenerative Medicine. He currently maintains his own consulting
business. Dr. Geesin has authored or coauthored 50 journal articles and
has conducted over 75 presentations at scientific conferences. He is
currently a member of the Wound Healing Society and the International
Cartilage Repair Society.
About SpinalCyte, LLC
Based in Houston, Texas, SpinalCyte, LLC is a spinal technology company
founded in 2007 for the purpose of developing an innovative and
autologous solution for nucleus replacement using human dermal
fibroblasts. The goal of SpinalCyte is to develop a nucleus regrowth
technology using autologous dermal cells harvested from the patient. To
date, SpinalCyte has been funded entirely by angel investors.
[ Back To TMCnet.com's Homepage ]